CORZIDE Drug Patent Profile

When do Corzide patents expire, and what generic alternatives are available?

Corzide is a drug marketed by King Pharms Llc and is included in one NDA.

The generic ingredient in CORZIDE is bendroflumethiazide; nadolol. There are four drug master file entries for this compound. Additional details are available on the bendroflumethiazide; nadolol profile page.

Summary for CORZIDE

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	42
Clinical Trials:	2
Drug Prices:	Drug price information for CORZIDE
DailyMed Link:	CORZIDE at DailyMed

See drug prices for CORZIDE

Recent Clinical Trials for CORZIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Mylan Pharmaceuticals	Phase 1

See all CORZIDE clinical trials

US Patents and Regulatory Information for CORZIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
King Pharms Llc	CORZIDE	bendroflumethiazide; nadolol	TABLET;ORAL	018647-001	May 25, 1983		DISCN	Yes	No
King Pharms Llc	CORZIDE	bendroflumethiazide; nadolol	TABLET;ORAL	018647-002	May 25, 1983		DISCN	Yes	No

Expired US Patents for CORZIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
King Pharms Llc	CORZIDE	bendroflumethiazide; nadolol	TABLET;ORAL	018647-001	May 25, 1983	3,935,267
King Pharms Llc	CORZIDE	bendroflumethiazide; nadolol	TABLET;ORAL	018647-001	May 25, 1983	3,982,021
King Pharms Llc	CORZIDE	bendroflumethiazide; nadolol	TABLET;ORAL	018647-002	May 25, 1983	3,982,021
King Pharms Llc	CORZIDE	bendroflumethiazide; nadolol	TABLET;ORAL	018647-002	May 25, 1983	3,935,267

International Patents for CORZIDE

See the table below for patents covering CORZIDE around the world.

Country	Patent Number	Title	Estimated Expiration
Hong Kong	34479	TETRAHYDRONAPHTHYLOXYAMINOPROPANOLS AND RELATED COMPOUNDS
Germany	2130393
Argentina	198638	PROCEDIMIENTO PARA PREPARAR 2,3-TRANS-1, 2, 3, 4-TETRAHIDRO-5--2,3-NAFTALENODIOLES
Japan	S54157550	MANUFACTURE OF TETRAHYDRONAPHTHALENE TRIOLS

CORZIDE Market Analysis and Financial Projection

Last updated: February 12, 2026

What Are the Market Dynamics for CORZIDE?

CORZIDE, a combination drug of labetalol and hydrochlorothiazide, is prescribed for hypertension management. Its market landscape is shaped by several factors:

• Market Size: The global antihypertensive drugs market was valued at approximately $34 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 4.5% from 2023 to 2030 [1].

• Patient Demographics: Rising prevalence of hypertension, particularly among adults aged 40-60, sustains demand. The World Health Organization reports 1.3 billion hypertensive adults globally, with low treatment rates in low-income regions.

• Competitive Landscape: The drug faces competition from other antihypertensive classes like ACE inhibitors, ARBs, calcium channel blockers, and diuretics. Generic versions of labetalol and hydrochlorothiazide are widely available, exerting pricing pressures.

• Regulatory Factors: Changes in prescribing guidelines, such as increased emphasis on patient-specific therapy, influence usage patterns. The U.S. FDA’s support for fixed-dose combination therapies facilitates market retention.

• Reimbursement Policies: Insurance coverage in developed markets tends to favor established treatments like CORZIDE, but variations exist across regions, affecting market penetration.

What Is the Financial Trajectory for CORZIDE?

Financial outlook relies on sales figures, patent status, pricing strategies, and market penetration:

• Sales Data: Exact revenue figures for CORZIDE are not publicly disclosed; however, antihypertensive drugs generate substantial revenue. Estimated worldwide sales of Labetalol/Hydrochlorothiazide combination drugs are around $700 million annually [2].

• Pricing Trends: Cost per unit varies widely; in the U.S., the average wholesale price is approximately $0.50 per tablet. The availability of generics limits pricing power but ensures broad access.

• Patent and Exclusivity: CORZIDE’s components are off patent, which constrains margins. No recent patent extensions are reported, indicating limited exclusivity.

• Market Penetration: Widely adopted in primary care, especially in North America and Europe. Adoption rates fluctuate with guideline updates and clinician preferences.

• Forecasting: The steady growth in hypertension prevalence suggests a stable long-term demand. However, price reductions and generic competition could suppress profit margins over time.

How Do Regulatory and Market Forces Affect CORZIDE?

Regulations impact market trajectories:

• Guideline Influence: The American Heart Association's 2020 updates reinforce the use of combination therapy for resistant hypertension, which benefits CORZIDE’s market presence [3].

• Reimbursement Policies: Medicaid, Medicare, and private insurers typically reimburse generic antihypertensives fully, encouraging use.

• Global Access: Markets in developing countries show slower adoption due to cost and healthcare infrastructure limitations.

What Are the Growth Opportunities and Risks?

Opportunities:

• Expanding use in resistant hypertension cases.

• Developing fixed-dose combinations with newer agents.

• Increasing access in emerging markets.

Risks:

• Market saturation due to generic competition.

• Shifts toward newer drug classes with better efficacy profiles.

• Regulatory constraints limiting off-label or new indications.

Key Takeaways

• The pharmaceutical market for CORZIDE is characterized by mature generic competition and stable demand driven by hypertension prevalence.

• Pricing pressures and patent expirations limit profitability; sales are primarily influenced by volume, reimbursement policies, and clinical guidelines.

• Market growth depends largely on regional healthcare infrastructure, physician prescribing habits, and emerging market access.

• Its financial future hinges on market penetration in resistant hypertension and potential formulation innovations.

FAQs

1. What is the patent status of CORZIDE?
CORZIDE’s components, labetalol and hydrochlorothiazide, are off patent, leading to widespread generic availability and limited exclusivity.

2. How does CORZIDE compare to other antihypertensive drugs?
It offers the convenience of combination therapy but faces competition from newer, branded drugs with potentially better side-effect profiles.

3. Are there any recent approvals or regulatory changes impacting CORZIDE?
No recent approvals; however, guidelines favoring combination treatment support its continued use.

4. What are the primary markets for CORZIDE?
United States, Europe, and certain emerging markets where hypertension management is prioritized.

5. What is the outlook for profits in the next five years?
Profitability will likely be stable or declining due to generic competition, unless market expansion or formulation innovation occurs.

---

References

[1] Fortune Business Insights, "Global Antihypertensive Drugs Market," 2022 report.
[2] IMS Health, "Pharmaceutical Market Data," 2022.
[3] American Heart Association, "2020 Guideline for the Management of Hypertension," 2020.